Overview

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Status:
Recruiting

Trial end date:
2022-11-25

Target enrollment:

Participant gender:

Summary

The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Collaborator:

Idera Pharmaceuticals, Inc.

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel